Clinical trial registry record

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated November 14, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02462889
Last registry update
November 14, 2025
Status
Completed
Phase
Phase 2
Sponsor
Jeffrey S Heier
Enrollment
128
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · PREVENTION · SINGLE
Evidence population
Human clinical study registration
Participants
128
Population
ALL
Duration
2015-06-01 to 2019-03-01
Intervention
Intravitreal aflibercept injection; Placebo
Comparator
Placebo
Outcomes measured
Percentage of Subjects Converting to Exudative AMD at 24 Months. — 24 months; Percentage of Patients Converted to Exudative AMD Who Had Exudative AMD in Fellow Eye ≤ 2 Years at Baseline. — up to Mo…; Percentage of Patient Converted to Exudative AMD Based on Presence of Nonexudative CNV. — up to Month 24; Mean Change in Best-corrected Visual Acuity at 24 Months Compared to Baseline — 24 months; Mean Change in Growth of Geographic Atrophy. — 24 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON